Drug Discovery and Development, Third Edition
3rd Edition
Published on 21. November 2019
696 pages
978-1-351-62514-2 (ISBN)
Description
Drug Discovery and Development, Third Edition presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing. This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Features:
Highlights emerging scientific fields relevant to drug discovery such as the microbiome, nanotechnology, and cancer immunotherapy; and novel research tools such as CRISPR and DNA-encoded libraries
Case study detailing the discovery of the anti-cancer drug, lorlatinib
Venture capitalist commentary on trends and best practices in drug discovery and development
Comprehensive review of regulations and their impact on drug development, highlighting special populations, orphan drugs, and pharmaceutical compounding
Multidiscipline functioning of an Academic Research Enterprise, plus a chapter on Ethical Concerns in Research
Contributions by 70+ experts from industry and academia specialists who developed and are practitioners of the science and business
Features:
Highlights emerging scientific fields relevant to drug discovery such as the microbiome, nanotechnology, and cancer immunotherapy; and novel research tools such as CRISPR and DNA-encoded libraries
Case study detailing the discovery of the anti-cancer drug, lorlatinib
Venture capitalist commentary on trends and best practices in drug discovery and development
Comprehensive review of regulations and their impact on drug development, highlighting special populations, orphan drugs, and pharmaceutical compounding
Multidiscipline functioning of an Academic Research Enterprise, plus a chapter on Ethical Concerns in Research
Contributions by 70+ experts from industry and academia specialists who developed and are practitioners of the science and business
Reviews / Votes
This third edition, written by experts from around the world, is expected to be useful for scientists working in this field. Each team in the drug discovery and development group will find some useful information in this book. There are many books in this area, but this one appears to discuss the topics in a bit greater detail.- Rahmat M. Talukder, PhD, RPh (The University of Texas at Tyler
More details
Edition
3rd edition
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
Professional and scholarly
Illustrations
42 Tables, black and white; 20 Line drawings, color; 70 Line drawings, black and white; 1 Halftones, color; 7 Halftones, black and white; 21 Illustrations, color; 77 Illustrations, black and white
ISBN-13
978-1-351-62514-2 (9781351625142)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
James J. O'Donnell | John Somberg | Vincent Idemyor
Drug Discovery and Development, Third Edition
Book
06/2021
3rd Edition
CRC Press
€69.00
Shipment within 10-20 days
James J. O'Donnell | John Somberg | Vincent Idemyor
Drug Discovery and Development, Third Edition
Book
12/2019
3rd Edition
CRC Press
€327.37
Shipment within 10-20 days
Persons
James J. O'Donnell, James T. O'Donnell
Content
Acknowledgments
Introduction to the First Edition (1992)
Introduction to the Second Edition (2006)
Editors
Contributors
Chapter 1 Introduction to Drug Discovery and Development
James J. O'Donnell III, John C. Somberg, and James T. O'Donnell
SECTION I Overview
Chapter 2 Current Opinions on the Trajectory of the Pharmaceutical Development
John C. Somberg
Chapter 3 Innovation in Drug Development: Perspectives of a Venture Capitalist
Krishna Yeshwant
SECTION II Drug Discovery
Chapter 4 High-Throughput Screening
Omar Perez, J. Pena, Virneliz Fernandez-Vega, Louis Scampavia, and Timothy Spicer
Chapter 5 DNA-Encoded Compound Libraries: An Emerging Paradigm in Drug Hit Discovery
Raphael M. Franzini
Chapter 6 Bio-Targeted Nanomaterials for Theranostic Applications
Sabyasachi Maiti and Kalyan Kumar Sen
Chapter 7 The Development of Adoptive T-Cell Immunotherapies for Cancer: Challenges and Prospects
David J. Dow, Steven J. Howe, Mala K. Talekar, and Laura A. Johnson
Chapter 8 CRISPR in Drug Discovery
Chih-Shia Lee and Ji Luo
Chapter 9 Probiotics in the World: "Bugs-as-Drugs"
Thomas Kuntz, Madeline Kim, Elle Simone Hill, Mariana C. Salas Garcia, and Jack A. Gilbert
Chapter 10 Discovery and Early Development of the Next-Generation ALK Inhibitor, Lorlatinib (18): Agent for Non?Small-Cell Lung Cancer
Paul F. Richardson
SECTION III Drug Development
Chapter 11 Integrated Drug Product Development: From Lead Candidate Selection to Life-Cycle Management
Madhu Pudipeddi, Abu T.M. Serajuddin, Ankita V. Shah, and Daniel Mufson
Chapter 12 New Trends in Pharmacological and Pharmaceutical Profiling
Lyn Rosenbrier Ribeiro, Duncan Armstrong, Thierry Jean, and Jean-Pierre Valentin
Chapter 13 Pharmacokinetics?Pharmacodynamics in New Drug Development
Sarfaraz K. Niazi
Chapter 14 The Evolving Role of the Caco-2 Cell Model to Estimate Intestinal Absorption Potential and Elucidate Transport Mechanisms
Jibin Li and Ismael J. Hidalgo
Chapter 15 Preclinical Toxicology
Damani Parran
Chapter 16 Safety Pharmacology: Past, Present, and Future
Jean-Pierre Valentin, Annie Delaunois, Marie-Luce Rosseels, Vitalina Gryshkova, and Tim G. Hammond
Chapter 17 Ethical Concerns in Clinical Research
Jonathan C. Young and Lori Nesbitt
Chapter 18 Clinical Trials Methodology
John Somberg
Chapter 19 The Academic Research Enterprise
Crista Brawley, Mary Jane Welch, Jeff Oswald, Erin Kampschmidt, Jennifer Garcia, Allecia Harley, Shrijay Vijayan, John McClatchy, Stephanie Guzik, and Stephanie Tedford
Chapter 20 Clinical Testing Challenges in HIV/AIDS Research
Vincent Idemyor
Chapter 21 The Evolving Role of the Pharmacist in Clinical, Academic, and Industry Sectors
Gourang Patel and Stephanie Tedford
Chapter 22 Intellectual Property in the Drug Discovery Process
Martha M. Rumore and William Schmidt
Chapter 23 Drug Repurposing: Academic Clinician Research Endeavors
Kathleen Heneghan and Stephanie E. Tedford
SECTION IV Regulations
Chapter 24 The Role of the Regulatory Affairs Professional in Guiding New Drug Research, Development, and Approval
S. Albert Edwards
Chapter 25 Orphan Drug Development and Regulations
A.M. Lynch
Chapter 26 Development of Drug Products for Older Adults: Challenges, Solutions, and Regulatory Considerations
S.W. Johnny Lau, Darrell R. Abernethy, and Chandrahas Sahajwalla
Chapter 27 Clinical Pharmacology and Regulatory Concerns for Developing Drug Products for Pediatric Patients
Janelle M. Burnham and Gilbert J. Burckart
Chapter 28 Pharmacy Compounding Regulations
Loyd V. Allen, Jr. and Willis C. Triplett
Index
Introduction to the First Edition (1992)
Introduction to the Second Edition (2006)
Editors
Contributors
Chapter 1 Introduction to Drug Discovery and Development
James J. O'Donnell III, John C. Somberg, and James T. O'Donnell
SECTION I Overview
Chapter 2 Current Opinions on the Trajectory of the Pharmaceutical Development
John C. Somberg
Chapter 3 Innovation in Drug Development: Perspectives of a Venture Capitalist
Krishna Yeshwant
SECTION II Drug Discovery
Chapter 4 High-Throughput Screening
Omar Perez, J. Pena, Virneliz Fernandez-Vega, Louis Scampavia, and Timothy Spicer
Chapter 5 DNA-Encoded Compound Libraries: An Emerging Paradigm in Drug Hit Discovery
Raphael M. Franzini
Chapter 6 Bio-Targeted Nanomaterials for Theranostic Applications
Sabyasachi Maiti and Kalyan Kumar Sen
Chapter 7 The Development of Adoptive T-Cell Immunotherapies for Cancer: Challenges and Prospects
David J. Dow, Steven J. Howe, Mala K. Talekar, and Laura A. Johnson
Chapter 8 CRISPR in Drug Discovery
Chih-Shia Lee and Ji Luo
Chapter 9 Probiotics in the World: "Bugs-as-Drugs"
Thomas Kuntz, Madeline Kim, Elle Simone Hill, Mariana C. Salas Garcia, and Jack A. Gilbert
Chapter 10 Discovery and Early Development of the Next-Generation ALK Inhibitor, Lorlatinib (18): Agent for Non?Small-Cell Lung Cancer
Paul F. Richardson
SECTION III Drug Development
Chapter 11 Integrated Drug Product Development: From Lead Candidate Selection to Life-Cycle Management
Madhu Pudipeddi, Abu T.M. Serajuddin, Ankita V. Shah, and Daniel Mufson
Chapter 12 New Trends in Pharmacological and Pharmaceutical Profiling
Lyn Rosenbrier Ribeiro, Duncan Armstrong, Thierry Jean, and Jean-Pierre Valentin
Chapter 13 Pharmacokinetics?Pharmacodynamics in New Drug Development
Sarfaraz K. Niazi
Chapter 14 The Evolving Role of the Caco-2 Cell Model to Estimate Intestinal Absorption Potential and Elucidate Transport Mechanisms
Jibin Li and Ismael J. Hidalgo
Chapter 15 Preclinical Toxicology
Damani Parran
Chapter 16 Safety Pharmacology: Past, Present, and Future
Jean-Pierre Valentin, Annie Delaunois, Marie-Luce Rosseels, Vitalina Gryshkova, and Tim G. Hammond
Chapter 17 Ethical Concerns in Clinical Research
Jonathan C. Young and Lori Nesbitt
Chapter 18 Clinical Trials Methodology
John Somberg
Chapter 19 The Academic Research Enterprise
Crista Brawley, Mary Jane Welch, Jeff Oswald, Erin Kampschmidt, Jennifer Garcia, Allecia Harley, Shrijay Vijayan, John McClatchy, Stephanie Guzik, and Stephanie Tedford
Chapter 20 Clinical Testing Challenges in HIV/AIDS Research
Vincent Idemyor
Chapter 21 The Evolving Role of the Pharmacist in Clinical, Academic, and Industry Sectors
Gourang Patel and Stephanie Tedford
Chapter 22 Intellectual Property in the Drug Discovery Process
Martha M. Rumore and William Schmidt
Chapter 23 Drug Repurposing: Academic Clinician Research Endeavors
Kathleen Heneghan and Stephanie E. Tedford
SECTION IV Regulations
Chapter 24 The Role of the Regulatory Affairs Professional in Guiding New Drug Research, Development, and Approval
S. Albert Edwards
Chapter 25 Orphan Drug Development and Regulations
A.M. Lynch
Chapter 26 Development of Drug Products for Older Adults: Challenges, Solutions, and Regulatory Considerations
S.W. Johnny Lau, Darrell R. Abernethy, and Chandrahas Sahajwalla
Chapter 27 Clinical Pharmacology and Regulatory Concerns for Developing Drug Products for Pediatric Patients
Janelle M. Burnham and Gilbert J. Burckart
Chapter 28 Pharmacy Compounding Regulations
Loyd V. Allen, Jr. and Willis C. Triplett
Index
